Skip to main content
SpringerLink
Log in

Antihypertensive Medication and Quality of Life—Silent Treatment of a Silent Killer?

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Hypertension is one of the major killers in the modern world and one of the great ironies of the disease is that it has little or no immediate effect on affected individuals' quality of life (QOL). This makes treatment very difficult, as most medications will affect QOL negatively, either through side effects or through the change in life-style associated with chronic drug regimens. This review describes some of the conceptual background for QOL measurements and looks at the effects on QOL of different antihypertensive treatments available today. The latest addition to the range of antihypertensive drugs, angiotensin II-receptor blockers, may be a significant step forward in treatment, as their ease of dosing and excellent tolerability minimise negative effects on patients while their possible benefits on factors such as sexual function may even improve QOL in hypertensive patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organisation. Constitution of the World Health Organization. Geneva: WHOBasic Documents, 1948.

    Google Scholar 

  2. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: Development and final revision of a health status measure. Med Care 1981;19(8):787–805.

    Google Scholar 

  3. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: The health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9(5):789–793.

    Google Scholar 

  4. Hunt SM, McEwen J, McKenna SP. Measuring health status: A new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985;35(273):185–188.

    Google Scholar 

  5. Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis. The arthritis impact measurement scales. Arthritis Rheum 1980;23(2):146–152.

    Google Scholar 

  6. Wilson IB, Cleary PD. Linking clinical variables with healthrelated quality of life. A conceptual model of patient outcomes. JAMA 1995;273(1):59–65.

    Google Scholar 

  7. McHorney CA. Health status assessment methods for adults: Past accomplishments and future challenges. Annu Rev Public Health 1999;20:309–335.

    Google Scholar 

  8. Hennessy CH, Moriarty DG, Zack MM, Scherr PA, Brackbill R. Measuring health-related quality of life for public health surveillance. Public Health Rep 1994;109(5):665–672.

    Google Scholar 

  9. Centers for Disease Control and Prevention. Measuring Healthy Days. Atlanta, GA USA: CDC; 2000.

    Google Scholar 

  10. Calman KC. Quality of life in cancer patients-Ahypothesis. J Med Ethics 1984;10(3):124–127.

    Google Scholar 

  11. Gift HC, Atchison KA. Oral health, health, and health-related quality of life. Med Care 1995;33(suppl 11):NS57–NS77.

    Google Scholar 

  12. McHorney CA, Ware JE, Jr., Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31(3):247–263.

    Google Scholar 

  13. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30(6):473–483.

    Google Scholar 

  14. Greenfield S, Nelson EC. Recent developments and future issues in the use of health status assessment measures in clinical settings. Med Care 1992;30(suppl 5):MS23–MS41.

    Google Scholar 

  15. Dupuy H. The Psychological General Well-Being Index. In: Wenger N, Mattson M, Furberg C, Elinson J, eds. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: Le Jacq, 1984. p. 170–183.

    Google Scholar 

  16. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992;124(4):1017–1025.

    Google Scholar 

  17. Rector TS, Johnson G, Dunkman WB, et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(suppl 6):VI71–VI77.

    Google Scholar 

  18. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 1993;71(12):1106–1107.

    Google Scholar 

  19. Greer S. The psychological dimension in cancer treatment. Soc Sci Med 1984;18(4):345–349.

    Google Scholar 

  20. Bullinger M, Anderson R, Cella D, Aaronson N. Developing and evaluating cross-cultural instruments from minimum requirements to optimal models. Qual Life Res 1993;2(6):451–459.

    Google Scholar 

  21. Skevington SM. Investigating the relationship between pain and discomfort and quality of life, using the WHOQOL. Pain 1998;76(3):395–406.

    Google Scholar 

  22. Idler EL, Benyamini Y. Self-rated health and mortality: A review of twenty-seven community studies. J Health Soc Behav 1997;38(1):21–37.

    Google Scholar 

  23. Burstrom K, Johannesson M, Diderichsen F. Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 2001;55(1):51–69.

    Google Scholar 

  24. Krousel-Wood MA, Re RN. Health status assessment in a hypertension section of an internal medicine clinic. Am J Med Sci 1994;308(4):211–217.

    Google Scholar 

  25. Lam CL, Lauder IJ. The impact of chronic diseases on the health-related quality of life (HRQOL) of Chinese patients in primary care. Fam Pract 2000;17(2):159–166.

    Google Scholar 

  26. Nelson DA. An anthropological perspective on optimizing calcium consumption for the prevention of osteoporosis. Osteoporosis Int 1996;6:325–328.

    Google Scholar 

  27. Luft FC.STOPPINGat theCAPPPof good HOPE.Nephrol Dial Transplant 2000;15:451–452.

    Google Scholar 

  28. Pickering G, Cranston W, Pears M. The Treatment of Hypertension. Springfield, IL: Charles C Thomas, 1961.

    Google Scholar 

  29. Dustan H, Schneckloth R, Corcoran A, Page I. The effectiveness of long-term treatment of malignant hypertension. Circulation 1958;18:644–651.

    Google Scholar 

  30. Sokolow M, Perloff D. Five years' survival of consecutive patients with malignant hypertension treated with antihypertensive agents. Am J Cardiol 1960;6:858–863.

    Google Scholar 

  31. Farmer R, Gifford R, Hines E. Effect of medical treatment of severe hypertension: A follow-up of 161 patients with group 3 and group 4 hypertension. Arch Intern Med 1963;112:118–128.

    Google Scholar 

  32. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202(11):1028–1034.

    Google Scholar 

  33. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213(7):1143–1152.

    Google Scholar 

  34. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990;335(8693):827–838.

    Google Scholar 

  35. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356(9246):1955–1964.

    Google Scholar 

  36. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 2001;358(9290):1305–1315.

    Google Scholar 

  37. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755–1762.

    Google Scholar 

  38. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: Results from the health survey for England 1994. J Hypertens 1998;16(6):747–752.

    Google Scholar 

  39. Chamontin B, Poggi L, Lang T, et al. Prevalence, treatment, and control of hypertension in the French population: Data from a survey on high blood pressure in general practice, 1994. Am J Hypertens 1998;11(6, part 1):759–762.

    Google Scholar 

  40. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: Is the 'rule of halves' still valid? J Hum Hypertens 1997;11(4):213–220.

    Google Scholar 

  41. Hansson L. 'Why don't you do as I tell you?' Compliance and anti-hypertensive regimes. Int J Clin Pract 2002;56(3).

  42. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995;91(3):698–706.

    Google Scholar 

  43. Weir MR, Flack JM, Applegate WB. Tolerability, safety, and quality of life and hypertensive therapy: The case for lowdose diuretics.AmJMed 1996;101(3A):83S–92S.

    Google Scholar 

  44. Wiklund I, Halling K, Ryden-Bergsten T, Fletcher A. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press 1997;6(6):357–364.

    Google Scholar 

  45. Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf 1996;15(2):91–106.

    Google Scholar 

  46. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet 1999;354(9192):1751–756.

    Google Scholar 

  47. Benetos A, Consoli S, Safavian A, Dubanchet A, Safar M. Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. Am Heart J 2000;140(4):E11.

    Google Scholar 

  48. Lewis CE, Grandits A, Flack J, McDonald R, Elmer PJ. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the treatment of mild hypertension study. Arch Intern Med 1996;156(4):377–385.

    Google Scholar 

  49. Weir MR, Prisant LM, Papademetriou V, et al. Antihypertensive therapy and quality of life. Influence of blood pressure reduction, adverse events, and prior antihypertensive therapy. Am J Hypertens 1996;9(9):854–859.

    Google Scholar 

  50. Omvik P, Thaulow E, Herland OB, Eide I, Midha R, Turner RR. Along-term, double-blind, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: A multicentre study. Br J Clin Pract Suppl 1994;73:23–30.

    Google Scholar 

  51. Dahlof B, Lindholm LH, Carney S, Pentikainen PJ, Ostergren J. Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. LOA Study Group. J Hypertens 1997;15(11):1327–1335.

    Google Scholar 

  52. Kusek JW, Lee JY, Smith DE, et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American study of kidney disease and hypertension (AASK) pilot study. Control Clin Trials 1996;17(suppl 4):40S–46S.

    Google Scholar 

  53. Udelson JE, DeAbate CA, Berk M, et al. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am Heart J 2000;139(3):503–510.

    Google Scholar 

  54. Testa MA, Turner RR, Simonson DC, Krafcik MB, Calvo C, Luque-Otero M. Quality of life and calcium channel blockade with nifedipine GITS versus amlodipine in hypertensive patients in Spain. Gastrointestinal Therapeutic System. J Hypertens 1998;16(12 part 1):1839–1847.

    Google Scholar 

  55. Staessen JA, Fagard R, Thijs L, et al. Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350(9080):757–764.

    Google Scholar 

  56. Sheehy O, LeLorier J. Patterns of amlodipine and felodipine use in an elderly Quebec population. Can J Cardiol 2000;16(9):1109–1117.

    Google Scholar 

  57. de Hoon JN, Vanmolkot FH, van de Ven LL, Van Bortel LM. Quality of life comparison between bisoprolol and nifedipine retard in hypertension. Cardiovasc Drugs Ther 1997;11(3):465–471.

    Google Scholar 

  58. Berdah J, Guest M, Salvador M. [Study of the efficacy and safety of fosinopril in general practice in 19,435 hypertensive patients (FLIGHT Study)]. Ann Cardiol Angeiol (Paris) 1998;47(3):169–175.

    Google Scholar 

  59. Croog SH, Elias MF, Colton T, et al. Effects of antihypertensive medications on quality of life in elderly hypertensive women. Am J Hypertens 1994;7(4 part 1):329–339.

    Google Scholar 

  60. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117(3):234–242.

    Google Scholar 

  61. Fletcher AE, Palmer AJ, Bulpitt CJ. Coughwith angiotensin converting enzyme inhibitors: How much of a problem? J Hypertens Suppl 1994;12(2):S43–S47.

    Google Scholar 

  62. Curb JD, Pressel SL, Cutler JA, et al. Effect of diureticbased antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996;276(23):1886–1892.

    Google Scholar 

  63. Grimm RH, Jr., Grandits GA, Cutler JA, et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the treatment of mild hypertension study. Arch Intern Med 1997;157(6):638–648.

    Google Scholar 

  64. Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999;12(11 part 1):1130–1134.

    Google Scholar 

  65. Vanmolkot FH, de Hoon JN, van de Ven LL, Van Bortel LM. Impact of antihypertensive treatment on quality of life: Comparison between bisoprolol and bendrofluazide. J Hum Hypertens 1999;13(8):559–563.

    Google Scholar 

  66. Paran E, Anson O, Neumann L. The effects of diuretics on quality of life of hypertensive patients. J Hum Hypertens 1996;10(suppl 3):S147–S152.

    Google Scholar 

  67. Breckenridge A. Angiotensin converting enzyme inhibitors and quality of life.AmJ Hypertens 1991;4(1 part 2):79S–82S.

    Google Scholar 

  68. Dictionary of Medicines. Dictionary of Medicines. Oxford: Oxford University Press; 2000.

  69. Ostergren J, Storstein L, Karlberg BE, Tibblin G. Quality of life in hypertensive patients treated with either carvedilol or enalapril. Blood Press 1996;5(1):41–49.

    Google Scholar 

  70. McCorvey E, Jr., Wright JT, Jr., Culbert JP, McKenney JM, Proctor JD, Annett MP. Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients. Clin Pharm 1993;12(4):300–305.

    Google Scholar 

  71. Palmer AJ, Fletcher AE, Rudge PJ, Andrews CD, Callaghan TS, Bulpitt CJ. Quality of life in hypertensives treated with atenolol or captopril: A double-blind crossover trial. J Hypertens 1992;10(11):1409–1416.

    Google Scholar 

  72. Haria M, Plosker GL, Markham A. Felodipine/metoprolol: A review of the fixed dose controlled release formulation in the management of essential hypertension. Drugs 2000;59(1):141–157.

    Google Scholar 

  73. Bulpitt CJ, Connor M, Schulte M, Fletcher AE. Bisoprolol and nifedipine retard in elderly hypertensive patients: Effect on quality of life. J Hum Hypertens 2000;14(3):205–212.

    Google Scholar 

  74. Tregaskis BF, McDevitt DG. Beta-adrenoceptor-blocking drugs in the elderly. J Cardiovasc Pharmacol 1990;16(suppl 5):S25–S28.

    Google Scholar 

  75. Joint National Committee. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157(21):2413–2446.

    Google Scholar 

  76. Lind L, Pollare T, Berne C, Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J 1994;128(6 part 1):1177–1183.

    Google Scholar 

  77. Kostis J, Wilson A. Incidence of Angioedema in SOLVD. J Am Coll Cardiol 2002;39(5, suppl A).

  78. Philipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: Results of the HANE study. HANE Trial Research Group. BMJ 1997;315(7101):154–159.

    Google Scholar 

  79. Gibbs CR, Lip GY, Beevers DG. Angioedema due to ACE inhibitors: Increased risk in patients of African origin. Br J Clin Pharmacol 1999;48(6):861–865.

    Google Scholar 

  80. Gainer JV, Nadeau JH, Ryder D, Brown NJ. Increased sensitivity to bradykinin among African Americans. J Allergy Clin Immunol 1996;98(2):283–287.

    Google Scholar 

  81. Bristol-Myers Squibb Pr. Bristol-Myers Squibb Discloses Vanlev Data From Landmark Octave Study. New York, NY; 2002 March 20.

  82. Pharmacia Inc. Studies with Eplerenone, Pharmacia's investigational selective Aldosterone Blocker, Unveiled at 51 st Annual Scientific Sessions ofACC. Atlanta, GA; 2002 March 20.

  83. McKee AL, Jr., Schover LR. Sexuality rehabilitation. Cancer 2001;92(suppl 4):1008–1012.

    Google Scholar 

  84. Seidman SN, Roose SP, Menza MA, Shabsigh R, Rosen RC. Treatment of erectile dysfunction in men with depressive symptoms: Results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001;158(10):1623–1630.

    Google Scholar 

  85. Lubeck DP, Grossfeld GD, Carroll PR. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology 2001;58(2 suppl 1):94–99.

    Google Scholar 

  86. Yang CC, Bowen JR, Kraft GH, Uchio EM, Kromm BG. Cortical evoked potentials of the dorsal nerve of the clitoris and female sexual dysfunction in multiple sclerosis. J Urol 2000;164(6):2010–2013.

    Google Scholar 

  87. Bortz WM, 2nd, Wallace DH, Wiley D. Sexual function in 1,202 aging males: Differentiating aspects. J GerontolABiol Sci Med Sci 1999;54(5):M237–M241.

    Google Scholar 

  88. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: Results of the 'Cologne male survey'. Int J Impot Res 2000;12(6):305–311.

    Google Scholar 

  89. Stadberg E, Mattsson LA, Milsom I.Womens attitudes and knowledge about the climacteric period and its treatment.A Swedish population-based study. Maturitas 1997;27(2):109–116.

    Google Scholar 

  90. Matthias RE, Lubben JE, Atchison KA, Schweitzer SO. Sexual activity and satisfaction among very old adults: Results from a community-dwelling Medicare population survey. Gerontologist 1997;37(1):6–14.

    Google Scholar 

  91. Bansal S. Sexual dysfunction in hypertensive men.Acritical review of the literature. Hypertension 1988;12(1):1–10.

    Google Scholar 

  92. Hsueh WA. Sexual dysfunction with aging and systemic hypertension. Am J Cardiol 1988;61(16):18H–23H.

    Google Scholar 

  93. Weiss RJ. Effects of antihypertensive agents on sexual function. Am Fam Physician 1991;44(6):2075–2082.

    Google Scholar 

  94. Chang S, Fine R, Siegel D, Chesney M, Black D, Hulley S. The impact of diuretic therapy on reported sexual function. Arch Intern Med 1991;151(12):2402–2408.

    Google Scholar 

  95. Grimm RH, Jr., Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997;29(1 part 1):8–14.

    Google Scholar 

  96. Wassertheil-Smoller S, Oberman A, Blaufox MD, Davis B, Langford H. The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life.Am J Hypertens 1992;5(1):37–44.

    Google Scholar 

  97. Srilatha B, Adaikan PG, Arulkumaran S, Ng SC. Sexual dysfunction related to antihypertensive agents: Results from the animal model. Int J Impot Res 1999;11(2):107–113.

    Google Scholar 

  98. Kostis JB, Rosen RC, Brondolo E, Taska L, Smith DE, Wilson AC. Superiority of nonpharmacologic therapy compared to propranolol and placebo in men with mild hypertension: A randomized, prospective trial. Am Heart J 1992;123(2):466–474.

    Google Scholar 

  99. Perez-Stable EJ, Halliday R, Gardiner PS, et al. The effects of propranolol on cognitive function and quality of life:Arandomized trial among patients with diastolic hypertension. AmJMed 2000;108(5):359–365.

    Google Scholar 

  100. Sundar S, Rajan AG, Somani PN, Kumar K. The effects of antihypertensive agents on the quality of life in Indian hypertensives. Acta Cardiol 1991;46(2):227–235.

    Google Scholar 

  101. Paran E, Anson O, Neumann L. The effects of replacing betablockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients. Am J Hypertens 1996;9(12 part 1):1206–1213.

    Google Scholar 

  102. Fogari R, Zoppi A, Corradi L, Mugellini A, Poletti L, Lusardi P. Sexual function in hypertensive males treated with lisinopril or atenolol: A cross-over study. Am J Hypertens 1998;11(10):1244–1247.

    Google Scholar 

  103. Duncan LE, Lewis C, Jenkins P, Pearson TA. Does hypertension and its pharmacotherapy affect the quality of sexual function in women? Am J Hypertens 2000;13(6 Part 1):640–647.

    Google Scholar 

  104. Leenen FH, Wilson TW, Bolli P, et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: A randomized clinical trial using electronic monitoring. Can J Cardiol 1997;13(10):914–920.

    Google Scholar 

  105. Detry JM. Patient compliance and therapeutic coverage: Amlodipine versus nifedipine SR in the treatment of hypertension and angina: Interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on Patient Compliance. Clin Cardiol 1994;17(9 suppl 3):III12–III16.

    Google Scholar 

  106. Mounier-Vehier C, Bernaud C, Carre A, Lequeuche B, Hotton JM, Charpentier JC. Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slowrelease. Am J Hypertens 1998;11(4 part 1):478–486.

    Google Scholar 

  107. Sanson-Fisher RW, Clover K. Compliance in the treatment of hypertension. A need for action. Am J Hypertens 1995;8(10 part 2):82S–88S.

    Google Scholar 

  108. Bardage C, Isacson DG. Self-reported side-effects of antihypertensive drugs:Anepidemiological study on prevalence and impact on health-state utility. Blood Press 2000;9(6):328–334.

    Google Scholar 

  109. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International Union of Pharmacology, XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52(3):415–472.

    Google Scholar 

  110. Fogari R, de Gasparo M. Addressing those two that go together: the Angiotensin II receptors and their role in blood-flow regulation. Blood Press 2001;10(1):6–15.

    Google Scholar 

  111. Neutel J, Weber M, Pool J, et al. Valsartan, a new angiotensin II antagonist: Antihypertensive effects over 24 hours. Clin Ther 1997;19(3):447–458.

    Google Scholar 

  112. Greater Glasgow Health Services. The Glasgow Formulary 5th edn, Greater Glasgow Health Services; 1998.

  113. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54(2):299–311.

    Google Scholar 

  114. Bodin F. Pharmacological and clinical profile of valsartan. J Hypertens 2000;18(suppl 2):S1–S7.

    Google Scholar 

  115. Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999;12(4 part 1):414–417.

    Google Scholar 

  116. Hegner G, Faust G, Freytag F, Meilenbrock S, Sullivan J, Bodin F. Valsartan, A new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol 1997;52(3):173–7.

    Google Scholar 

  117. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996;60(3):341–346.

    Google Scholar 

  118. Cifkova R, Peleska J, Hradec J, et al. Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens 1998;12(8):563–567.

    Google Scholar 

  119. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000;18(1):89–95.

    Google Scholar 

  120. Baruch L, Anand I, Cohen I, Ziesche S, Judd D, Cohn JN. Augmented short-and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 1999;99(20):2658–2664.

    Google Scholar 

  121. Fogari R, Corradi I, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol. A cross over study. Am J Hypertens 2001;14(1):27–31.

    Google Scholar 

  122. Ruzbarsky V, Michal V. Morphologic changes in the arterial bed of the penis with aging: Relationship to the pathogenesis of impotence. Invest Urol 1977;15(3):194–199.

    Google Scholar 

  123. Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997;157(5):1920–1925.

    Google Scholar 

  124. Becker A, Uckert S, Stief C, et al. Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology 2001;57(1):193–198.

    Google Scholar 

  125. Wogen J, Kreilick CA, Livornese RC, Frech F. Apopulationbased study of compliance and persistency with cardiovascular agents used in hypertension management. Am J Hypertens 2001;14(4):112A.

    Google Scholar 

  126. Stewart E, Frech F, QD D, Bentkover J, Flores M, Bedigian M. Quality of life of patients switching hypertension medications to valsartan or valsartan/HCT. Am J Hypertens 2000;13(4):124A.

    Google Scholar 

  127. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996;34(3):220–233.

    Google Scholar 

  128. Dahlöf B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;369:995–1003.

    Google Scholar 

  129. Kjeldsen S, Julius S, Brunner H, et al. Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial. Blood Press 2001;10(2):83–91.

    Google Scholar 

  130. Stanton JA, Lowenthal DT. The evidence for lifestyle modification in lowering blood pressure in the elderly.AmJ Geriatr Cardiol 2000;9(1):27–33.

    Google Scholar 

  131. Schaub AF, Steiner A, Vetter W. Compliance to treatment. Clin Exp Hypertens 1993;15(6):1121–1130.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rutherglen Health Centre, 130 Stonelaw Road, Glasgow, G73 2PQ, Scotland

    A. Douglas Bremner

Authors
  1. A. Douglas Bremner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bremner, A.D. Antihypertensive Medication and Quality of Life—Silent Treatment of a Silent Killer?. Cardiovasc Drugs Ther 16, 353–364 (2002). https://doi.org/10.1023/A:1021790112182

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021790112182

Search

Navigation